FREE Keynote Passes

We think our Plenary Keynote Presentations are pretty outstanding and want to give them the biggest viewing audience possible. So, we're offering Complimentary Keynote Passes these last 2 weeks before Pharma R&D Week starts. Your Keynote Pass gives you access to (virtually) attend our Plenary Keynotes, Keynote Panel Discussions, Sponsored Presentations and Exhibits!

Receive Access to the Following Presentations:

TUESDAY, JUNE 15

SPONSORED PRESENTATION - Altis Biosystems
[From the Predictive Preclinical Models in Oncology Conference]
10:00 am — Introduction to Altis Biosystems
Niki Heinz, Director of Business Development, Altis Biosystems

IMPLEMENTING PRECISION MEDICINE AT BIG PHARMA

11:45 am PD-1 Antibodies Are Transforming Cancer Treatment as Precision Medicine Informed Mono- or Combination Therapy
Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development, CMO, Merck Research Laboratories
Precision medicine tools have enabled PD-1 antibody therapy to transform cancer care in a number of major tumor types. They have also provided insights to resistance biology and potential logical choices for combination therapies. Combination therapies with PD-1 antibodies as foundational are beginning to impact many therapeutic choices.

12:15 Precision Medicine Strategies: The Next Level
Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.
Recent advances and impact of precision medicine strategies in drug development will be reviewed. Technology advances using more spatially and cellularly precise high dimensional profiling will be addressed along with a few novel case studies of patient selection and mechanism-of-action biomarkers.

12:35 Keynote Panel Discussion: Implementing Precision Medicine at Big Pharma
Moderator:
Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development, CMO, Merck Research Laboratories

Panelists:
Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.

Elizabeth B. Somers, Senior Director, Diagnostic Pathway Lead, Alzheimer's Disease Franchise, Eisai, Inc.

Zhen Su, MD, MBA, Senior Vice President, Head of Global Oncology Franchise, EMD Serono, a business of Merck KGaA, Darmstadt, Germany

SPONSORED PRESENTATION - IVIM Technology
[From the Predictive Preclinical Models in Oncology Conference]
2:50 pm — IntraVital Microscopy (IVM): In Vivo Live Cell Imaging Platform
Pilhan Kim, PhD, Professor, KAIST; CEO, IVIM Technology

SPONSORED PRESENTATION - Olink
[From the Clinical Trials and Translational Biomarkers Conference]
4:05 pm — Actionable Protein Biomarkers to Accelerate Drug Development
Evan Mills, Director, Strategic Accounts, Olink

WEDNESDAY, JUNE 16

Choose from 2 Sponsored Presentations at 11:05 am.

SPONSORED PRESENTATION - Exosome Diagnostics, Inc.
[From the Liquid Biopsy and CTCs in Clinical Trials Conference]
11:05 am — Exosome-based Digital PCR for FGFR Testing in Bladder Cancer
Daniel Enderle, PhD, Scientific Director, CDx, Exosome Diagnostics, Inc.- a Bio-Techne Brand

SPONSORED PRESENTATION - Curi Bio
[From the 3D and iPS Cell Models for Drug Discovery Conference]
11:05 am — High-Trhoughput 3D Organ-on-chip Contractility Assays for Discovery of Novel Cardiac and Skeletal Muscle Therapies
Nicholas Geisse, PhD, Chief Science Officer, Curi Bio

BIG PHARMA RESPONSE TO COVID-19 PANDEMIC

12:10 pm AstraZeneca R&D: Turning Science into Medicine
Mene N. Pangalos, PhD, Executive Vice President, Biopharmaceuticals R&D, AstraZeneca

12:40 Reimagining Global Health through Artificial Intelligence: The Roadmap to AI Maturity
Ann Aerts, MD, Head, Novartis Foundation

SPONSORED PRESENTATION - Anatomic Incorporated.
[From the 3D and iPS Cell Models for Drug Discovery Conference]
2:40 pm — Characterization of a Scalable Human Nociceptor Population for Pain Therapeutics Development
Patrick Walsh, MS, Chief Executive Officer, Anatomic Incorporated

SPONSORED PRESENTATION -CELLINK Life Sciences
[From the 3D and iPS Cell Models for Drug Discovery Conference]
2:50 pm — Integrated Workflow for the High-Throughput Generation of iPSC Clones and Compound Screening for Drug Discovery
Elly Sinkala, PhD, Senior Application Scientist, CYTENA (A CELLINK Company)

Women in Science

4:15 Keynote Panel Discussion: Women in Science
Moderator:
Razelle Kurzrock, MD, CMO, Chair, Clinical Trials Committee, Worldwide Innovative Network (WIN) for Personalized Cancer Therapy

Panelists:
Emilee Connors, PhD, Scientific Director, Medical Affairs, Merck Research Labs

Lauren Leiman, Executive Director, BloodPAC

Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.

Theresa L. Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, University of Pittsburgh

THURSDAY, JUNE 17

INNOVATION FOR PHARMA R&D PRODUCTIVITY AND EFFICIENCY

12:25 pm Innovation in Drug Discovery
Stephen Rees, Vice President, Discovery Biology, AstraZeneca

12:55 Keynote Panel Discussion: Innovation for Pharma R&D Productivity and Efficiency
Moderator:
Cecilia Schott, PharmD, MBA, Head, Global Precision Medicine Strategy, Oncology Business Unit, Novartis

Panelists:
Jason Ekert, PhD, Senior Director & Head, Complex In Vitro Models, GlaxoSmithKline

Michael Jackson, PhD, Senior Vice President, Drug Discovery and Development, Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute

Emmett Schmidt, MD, PhD, Vice President, External Collaborations, Oncology Early Development, Merck

SPONSORED PRESENTATION - GERO
[From the Target Validation and Phenotypic Screening Conference]
2:50 pm — How AI Helps to Utilize Genetic, Transcriptomic and Clinical Data for Target Identification in Complex Diseases
Peter Fedichev, PhD, CEO, GERO